Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBITDA: 2011-2025

Historic EBITDA for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$189,000.

  • Fennec Pharmaceuticals' EBITDA rose 96.37% to -$189,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 376.90%. This contributed to the annual value of $2.6 million for FY2024, which is 120.11% up from last year.
  • Fennec Pharmaceuticals' EBITDA amounted to -$189,000 in Q3 2025, which was up 93.08% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' EBITDA ranged from a high of $13.7 million in Q1 2024 and a low of -$9.6 million during Q4 2022.
  • Its 3-year average for EBITDA is -$1.3 million, with a median of -$1.8 million in 2023.
  • Examining YoY changes over the last 5 years, Fennec Pharmaceuticals' EBITDA showed a top increase of 360.78% in 2024 and a maximum decrease of 411.50% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' EBITDA stood at -$4.2 million in 2021, then plummeted by 89.29% to -$9.6 million in 2022, then surged by 81.01% to -$1.8 million in 2023, then surged by 48.62% to -$934,000 in 2024, then surged by 96.37% to -$189,000 in 2025.
  • Its last three reported values are -$189,000 in Q3 2025, -$2.7 million for Q2 2025, and -$808,000 during Q1 2025.